Iza-Bren Doubles Median Progression-Free Survival in Phase 3 Lung Cancer Study
SystImmune said parent company Biokin reported positive results from a prespecified interim analysis of the PANKU-Lung01 study, comparing Iza-Bren with chemotherapy in previously treated EGFR-mutated non-small cell lung cancer.
Story updates
07:30:38 AM UTC
SquawkNews
Bristol-Myers Squibb Company reported that izalontamab brengitecan doubled median PFS to 11.1 months vs 5.7 with platinum chemo in EGFR-mutated NSCLC post-TKI (HR 0.40; p<0.0001). OS data are immature; safety was manageable with low discontinuations.Material DetailsContext by AI AnalystThis is a mi…
SystImmune, Inc. (SystImmune), a clinical stage biotechnology company, and Bristol Myers Squibb (NYSE:BMY) today announced that SystImmune’s parent company Sichuan Biokin Pharmaceutical, Ltd. (Biokin) reported positive results from a prespecified interim analysis in the randomized, multicenter Phas…